Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04605588 · ClinicalTrials.gov registry record · Phase 2
A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19
A Phase 2 study, sponsored by Rutgers, The State University of New Jersey.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT04605588: Clinical Trial Phase 2 study, sponsored by Rutgers, The State University of New Jersey.
NCT04605588 is a Phase 2 study that was terminated before completion, run by Rutgers, The State University of New Jersey. The registered enrollment target is 7 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04605588, a Phase 2 study, was terminated before completion, sponsored by Rutgers, The State University of New Jersey.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
New outpatient treatments for COVID-19 are urgently needed. There is some evidence that a combination of three medications currently used to treat other viral infections could be effective in fighting this new virus. The purpose of this trial is to evaluate the efficacy of Nitazoxanide (NTZ), Ribavirin (RBV) and Hydroxychloroquine (HCQ) versus placebo in participants with proven SARS-CoV-2 infection The study will enroll 70 participants within the 7 days after having been diagnosed with coronavirus infection. The purpose is to determine if those randomized to 5-day dosing with the three medication combination have decreased viral load and severity of illness in the 10 days following treatment as compared to those taking placebo. Participants will be actively followed for 28 days.
Primary Outcome
qPCR measured via nasal swab
Interventions
- DRUG Hydroxychloroquine
- DRUG Ribavirin
- DRUG Nitazoxanide
- DRUG Placebo Nitazoxanide
- DRUG Placebo Ribavirin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2020-12-02 |
| Est. Completion | 2021-02-04 |
| Phase | Phase 2 |
Why NCT04605588 stopped before completion
NCT04605588 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 5 interventions - of which Hydroxychloroquine is the first listed.
NCT04605588 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04605588 about?
NCT04605588 is a clinical study titled "A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19". New outpatient treatments for COVID-19 are urgently needed. There is some evidence that a combination of three medications currently used to treat other viral infections could be effective in fighting this new virus. The purpose of this trial is to evaluate the efficacy of Nitazoxanide (NTZ), Ribavi...
What is the current status of trial NCT04605588?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2020-12-02. Estimated completion is 2021-02-04.
What interventions are being tested in trial NCT04605588?
The interventions under investigation include: Hydroxychloroquine (DRUG), Ribavirin (DRUG), Nitazoxanide (DRUG), Placebo Nitazoxanide (DRUG), Placebo Ribavirin (DRUG).
Who is sponsoring clinical trial NCT04605588?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04605588's enrollment target sits among peer trials
7 1996th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI